Oxford Science Enterprises
VC Fund
Oxford, United Kingdom
Oxford Science Enterprises is a VC fund in Oxford focused on Health Care and Biotechnology. Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
- Total investments:
- 210
- Last investment:
- Lead investor:
- 39%
- Fund size:
- $299M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Oxford Science Enterprises invests in
Stages Oxford Science Enterprises invests in
Countries Oxford Science Enterprises invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $1.3M–$12M
- Series A
- $6.3M–$45M
- Series B
- $9.1M–$168M
Investment Focus
Industry
- Health Care 34 (16%)
- Biotechnology 33 (16%)
- Medical 16 (8%)
- Therapeutics 16 (8%)
- Software 15 (7%)
Stage
- Seed 67 (32%)
- Series A 51 (24%)
- Series B 21 (10%)
- Venture - Series Unknown 11 (5%)
- Series C 10 (5%)
Country
- United Kingdom 91 (43%)
- United States 7 (3%)
- Finland 1 (0%)
- The Netherlands 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexis Dormandy
Chief Executive Officer
|
Chief Executive Officer | Total investments: 1 | Find email | |
|
Alexis Zervoglos
Senior Partner (Technology)
|
Senior Partner (Technology) | Total investments: 3 | Find email | |
Claire Brown
Partner ( Life Sciences)
|
Partner ( Life Sciences) | Total investments: 3 | Find email | |
Ekaterina Smirnyagina
Senior Partner and Head of Life Sciences
|
Senior Partner and Head of Life Sciences | Total investments: 6 | Find email | |
David Norwood
Chairman
|
Chairman | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $310M / Series C / Oct 15, 2026 | ||
| Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany. | $125M / Series B / Oct 14, 2026 | ||
| Sensible Biotechnologies is developing world's first cell-based platform to unlock the next generation of mRNA medicines. | $27M / Series A / Oct 06, 2026 | ||
| Living Optics is commercializing next generation imaging technology which leverages a compact camera system based on breakthroughs in hardware design and software processing. | $20M / Series A / Sep 24, 2026 | ||
| ReEmerge is a medical technology company that develops Cognitive Network Restoration Therapy, a neurostimulation approach designed to address chronic cognitive impairment following brain injury. Its technology uses targeted electrical stimulation of neural networks to activate underperforming but viable brain circuits, with the goal of improving cognitive function and supporting recovery in patients with persistent impairments. | $37M / Series A / Sep 15, 2026 | ||
| MCatalysis is a deep tech startup developing microwave catalysis technology to convert waste carbon resources such as agricultural residues, plastic waste, and waste gas streams into low-cost, clean synthetic fuels and chemicals at petrochemical cost parity. | $5M / Seed / Sep 09, 2026 | ||
| Singular Machines is an engineering automation company that provides solutions to engineering issues. | Pre-Seed / Aug 03, 2026 | ||
| Mirae provides an AI-powered patient companion and precision medicine platform for people living with complex chronic diseases, beginning with inflammatory bowel disease. Its mobile application lets users record symptoms, food, medications, laboratory results, and other health information. The platform can connect permitted electronic healthrecords and wearable data to help users review possible patterns and prepare summaries for healthcare appointments. Mirae also develops disease and symptom models that analyze patient-reported and clinical events for healthcare organizations and research activities. The platform does not provide medical diagnosis, prescriptions, or clinical care. | $5.4M / Seed / Jul 28, 2026 | ||
| Vivid Dx is a diagnostics company that focuses on pathogen detection and antimicrobial resistance testing services. | $15M / Seed / Jul 28, 2026 | ||
| MoA Technology Limited is a plant genetics company spun out from the University of Oxford. Professor Liam Dolan, FRS, has developed an innovative approach for the discovery of agricultural technologies that will enable farmers to produce healthy food from sustainable crop systems. | $29.7M / Series C / Jul 23, 2026 | ||
| See all 210 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Oxford Science Enterprises invest in?
Oxford Science Enterprises invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 210 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Oxford Science Enterprises invest in?
Oxford Science Enterprises typically joins rounds of $1.3M–$12M at Seed, $6.3M–$45M at Series A and $9.1M–$168M at Series B. These are whole funding-round sizes, not Oxford Science Enterprises's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Oxford Science Enterprises took part in.
How do I contact Oxford Science Enterprises?
Public channels for Oxford Science Enterprises include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Oxford Science Enterprises?
The team at Oxford Science Enterprises includes Alexis Dormandy (Chief Executive Officer), Alexis Zervoglos (Senior Partner (Technology)) and Claire Brown (Partner ( Life Sciences)), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
